Home Stock

Stock Research: Aurobindo Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Aurobindo Pharma

NSEI:AUROPHARMA INE406A01037
62
  • Value
    80
  • Growth
    77
  • Safety
    Safety
    42
  • Combined
    85
  • Sentiment
    29
  • 360° View
    360° View
    62
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aurobindo Pharma Limited is an India-based pharmaceutical company. It operates in the pharmaceuticals industry, focusing on active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company markets its products globally in approximately 150 countries. In the last fiscal year, the company had a market cap of $7790 million, profits of $2188 million, and revenue of $3713 million.

more
Strongest Rank Market Pulse
Weakest Rank Price vs. Earnings (P/E)
Country India
Industry Pharmaceuticals
Size Medium
Website aurobindo.com
Index
Good Governace Growth Markets
Independent Boards Growth Markets
Low Waste
Aurobindo Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
80 75 73 83
Growth
77 67 79 37
Safety
Safety
42 41 43 81
Sentiment
29 59 53 33
360° View
360° View
62 73 84 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
67 64 64 74
Opinions Change
40 37 53 50
Pro Holdings
n/a 72 45 16
Market Pulse
17 18 38 35
Sentiment
29 59 53 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
80 75 73 83
Growth
77 67 79 37
Safety Safety
42 41 43 81
Combined
85 83 85 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
85 81 82 89
Price vs. Earnings (P/E)
76 73 82 87
Price vs. Book (P/B)
79 73 80 86
Dividend Yield
32 39 34 36
Value
80 75 73 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
68 56 38 33
Profit Growth
29 42 88 58
Capital Growth
84 52 29 84
Stock Returns
51 73 100 7
Growth
77 67 79 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
30 32 40 42
Refinancing
85 78 82 90
Liquidity
25 38 40 76
Safety Safety
42 41 43 81

Similar Stocks

Discover high‑ranked alternatives to Aurobindo Pharma and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Fleury

BOVESPA:FLRY3
Country: Brazil
Industry: Health Care Services
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews